Breast Cancer Coverage from Every Angle

Shanu Modi, MD, on Clinical Implications of New Findings on T-DXd for Metastatic Breast Cancer

Posted: Monday, June 13, 2022

Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses the practical clinical issues of phase III findings from the DESTINY-Breast04 trial, which compared fam-trastuzumab deruxtecan-nxki (T-DXd) vs treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer. If, as the data suggest, T-DXd proves to be the new standard of care for this population, clinicians will need to know who the ideal candidates for therapy are and how to manage potential side effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.